IL273838A - Peptide oligonucleotide conjugates ,compositions comprising the same and uses thereof - Google Patents

Peptide oligonucleotide conjugates ,compositions comprising the same and uses thereof

Info

Publication number
IL273838A
IL273838A IL273838A IL27383820A IL273838A IL 273838 A IL273838 A IL 273838A IL 273838 A IL273838 A IL 273838A IL 27383820 A IL27383820 A IL 27383820A IL 273838 A IL273838 A IL 273838A
Authority
IL
Israel
Prior art keywords
compositions
same
oligonucleotide conjugates
peptide oligonucleotide
peptide
Prior art date
Application number
IL273838A
Other languages
Hebrew (he)
Other versions
IL273838B (en
Original Assignee
Sarepta Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/101,942 external-priority patent/US20110269665A1/en
Priority claimed from US13/107,528 external-priority patent/US9238042B2/en
Application filed by Sarepta Therapeutics Inc filed Critical Sarepta Therapeutics Inc
Publication of IL273838A publication Critical patent/IL273838A/en
Publication of IL273838B publication Critical patent/IL273838B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A61K47/6455—Polycationic oligopeptides, polypeptides or polyamino acids, e.g. for complexing nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL273838A 2011-05-05 2011-11-17 Peptide oligonucleotide conjugates ,compositions comprising the same and uses thereof IL273838B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13/101,942 US20110269665A1 (en) 2009-06-26 2011-05-05 Compound and method for treating myotonic dystrophy
US13/107,528 US9238042B2 (en) 2010-05-13 2011-05-13 Antisense modulation of interleukins 17 and 23 signaling
PCT/US2011/061282 WO2012150960A1 (en) 2011-05-05 2011-11-17 Peptide oligonucleotide conjugates

Publications (2)

Publication Number Publication Date
IL273838A true IL273838A (en) 2020-05-31
IL273838B IL273838B (en) 2022-09-01

Family

ID=45218873

Family Applications (2)

Application Number Title Priority Date Filing Date
IL273838A IL273838B (en) 2011-05-05 2011-11-17 Peptide oligonucleotide conjugates ,compositions comprising the same and uses thereof
IL229227A IL229227B (en) 2011-05-05 2013-11-04 Peptide oligonucleotide conjugates ,compositions comprising the same and uses thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL229227A IL229227B (en) 2011-05-05 2013-11-04 Peptide oligonucleotide conjugates ,compositions comprising the same and uses thereof

Country Status (8)

Country Link
EP (1) EP2704749A1 (en)
JP (6) JP6478632B2 (en)
KR (3) KR102339196B1 (en)
CN (2) CN103619356B (en)
AU (5) AU2011367230B2 (en)
CA (2) CA2834128A1 (en)
IL (2) IL273838B (en)
WO (1) WO2012150960A1 (en)

Families Citing this family (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2206781B1 (en) 2004-06-28 2015-12-02 The University Of Western Australia Antisense oligonucleotides for inducing exon skipping and methods of use thereof
WO2006086667A2 (en) 2005-02-09 2006-08-17 Avi Bio Pharma, Inc. Antisense composition and method for treating muscle atrophy
NZ574807A (en) 2006-08-11 2011-01-28 Prosensa Technologies Bv Methods and means for treating dna repeat instability associated genetic disorders
US20100016215A1 (en) 2007-06-29 2010-01-21 Avi Biopharma, Inc. Compound and method for treating myotonic dystrophy
CN101896186A (en) 2007-10-26 2010-11-24 莱顿教学医院 The mode and the method for antagonism disorder of muscle
EP2119783A1 (en) 2008-05-14 2009-11-18 Prosensa Technologies B.V. Method for efficient exon (44) skipping in Duchenne Muscular Dystrophy and associated means
SI3133160T1 (en) 2008-10-24 2019-05-31 Sarepta Therapeutics, Inc. Exon skipping compositions for dmd
ES2693459T3 (en) 2009-11-12 2018-12-11 The University Of Western Australia Antisense molecules and methods for the treatment of pathologies
TWI541024B (en) 2010-09-01 2016-07-11 日本新藥股份有限公司 Antisense nucleic acid
US20130085139A1 (en) 2011-10-04 2013-04-04 Royal Holloway And Bedford New College Oligomers
CA2854907C (en) * 2011-11-18 2020-03-10 Sarepta Therapeutics, Inc. Functionally-modified oligonucleotides and subunits thereof
JP6317675B2 (en) 2011-11-30 2018-04-25 サレプタ セラピューティクス， インコーポレイテッド Oligonucleotides for treating prolonged repeat disease
ES2727481T3 (en) 2011-11-30 2019-10-16 Sarepta Therapeutics Inc Indon-induced inclusion of spinal muscular atrophy
RS57467B1 (en) 2011-12-08 2018-09-28 Sarepta Therapeutics Inc Oligonucleotide analogues targeting human lmna
EP4043039A1 (en) 2012-01-27 2022-08-17 BioMarin Technologies B.V. Rna modulating oligonucleotides with improved characteristics for the treatment of duchenne and becker muscular dystrophy
EP4400169A2 (en) 2012-04-23 2024-07-17 Vico Therapeutics B.V. Rna modulating oligonucleotides with improved characteristics for the treatment of neuromuscular disorders
EP3885439A1 (en) 2012-12-20 2021-09-29 Sarepta Therapeutics, Inc. Improved exon skipping compositions for treating muscular dystrophy
US9856474B2 (en) 2013-01-16 2018-01-02 Iowa State University Research Foundation, Inc. Deep intronic target for splicing correction on spinal muscular atrophy gene
EP3633035A1 (en) 2013-03-14 2020-04-08 Sarepta Therapeutics, Inc. Exon skipping compositions for treating muscular dystrophy
MX366274B (en) 2013-03-14 2019-07-04 Sarepta Therapeutics Inc Exon skipping compositions for treating muscular dystrophy.
BR112015022998A2 (en) 2013-03-15 2017-11-14 Sarepta Therapeutics Inc improved compositions for treating muscular dystrophy
CN105228999B (en) 2013-05-24 2021-03-02 味之素株式会社 Process for preparing morpholino oligonucleotides
JP6618910B2 (en) 2013-09-05 2019-12-11 サレプタ セラピューティクス，インコーポレイテッド Inclusion of antisense-induced exon 2 in acid α-glucosidase
UA117768C2 (en) 2013-12-24 2018-09-25 Сентісс Фарма Прайвет Лімітед Topical brimonidine tartrate ophthalmic solution
TR201901939T4 (en) * 2014-03-12 2019-03-21 Nat Center Neurology & Psychiatry Antisense nucleic acid.
KR101661277B1 (en) * 2014-03-17 2016-09-30 제주광어주식회사 Single point nucleotide changed Live Attenuated Viral Hemorrhagic Septicemia Virus
JP6901966B2 (en) 2014-05-16 2021-07-14 オレゴン ステート ユニバーシティ Antisense antibacterial compounds and methods
CA2948568A1 (en) 2014-05-19 2015-11-26 David Greenberg Antisense antibacterial compounds and methods
WO2016040748A1 (en) 2014-09-12 2016-03-17 Ionis Pharmaceuticals, Inc. Compositions and methods for detection of smn protein in a subject and treatment of a subject
EP3240794A4 (en) 2014-12-31 2018-10-31 Oregon State University Antisense antibacterial compounds and methods
WO2016138534A2 (en) * 2015-02-27 2016-09-01 Sarepta Therapeutics, Inc. Antisense-induced exon2 inclusion in acid alpha-glucosidase
MA41795A (en) 2015-03-18 2018-01-23 Sarepta Therapeutics Inc EXCLUSION OF AN EXON INDUCED BY ANTISENSE COMPOUNDS IN MYOSTATIN
EP3297649B1 (en) * 2015-05-19 2023-10-11 Sarepta Therapeutics, Inc. Peptide oligonucleotide conjugates
US10849917B2 (en) 2015-06-01 2020-12-01 Sarepta Therapeutics, Inc. Antisense-induced exon exclusion in type VII collagen
WO2016196897A1 (en) 2015-06-04 2016-12-08 Sarepta Therapeutics, Inc. Methods and compounds for treatment of lymphocyte-related diseases and conditions
ES2907629T3 (en) * 2015-08-05 2022-04-25 Eisai R&D Man Co Ltd A method for preparing a substantially diastereomerically pure phosphorodiamidate oligomer, a phosphorodiamidate oligomer prepared by said method and a pharmaceutical composition comprising said phosphorodiamidate oligomer
CA2996164A1 (en) * 2015-08-28 2017-03-09 Sarepta Therapeutics, Inc. Modified antisense oligomers for exon inclusion in spinal muscular atrophy
CN108350030B (en) * 2015-09-10 2022-12-13 汉阳大学校产学协力团 Skin permeable peptides and methods of use thereof
CN108699555A (en) 2015-10-09 2018-10-23 萨勒普塔医疗公司 Composition for treating Duchenne's dystrophy and associated disease and method
GB2545898B (en) 2015-12-21 2019-10-09 Sutura Therapeutics Ltd Improved drug delivery by conjugating oligonucleotides to stitched/stapled peptides
US10907158B2 (en) 2015-12-23 2021-02-02 Board Of Regents, The University Of Texas System Antisense antibacterial compounds and methods
JP7393121B2 (en) 2015-12-23 2023-12-06 オレゴン ステイト ユニバーシティー Antisense antibacterial compounds and methods
EA201892366A1 (en) 2016-04-18 2019-03-29 Сарепта Терапьютикс, Инк. ANTISMINAL OLIGOMERS AND METHODS OF THEIR APPLICATION FOR THE TREATMENT OF DISEASES ASSOCIATED WITH THE GENE OF THE ACID ALPHA-GLUCOSIDASE
MA45616A (en) 2016-04-29 2019-03-06 Sarepta Therapeutics Inc TARGET OLIGONUCLEOTIDE ANALOGUES LMNA HUMAN
WO2018005805A1 (en) * 2016-06-30 2018-01-04 Sarepta Therapeutics, Inc. Exon skipping oligomers for muscular dystrophy
JP7022079B2 (en) * 2016-06-30 2022-02-17 サレプタ セラピューティクス， インコーポレイテッド Process for preparing phosphorodiamidart morpholino oligomers
PL3554552T3 (en) * 2016-12-19 2022-11-21 Sarepta Therapeutics, Inc. Exon skipping oligomer conjugates for muscular dystrophy
DK3554553T3 (en) * 2016-12-19 2022-09-19 Sarepta Therapeutics Inc EXON-SKIPPING OLIGOMER CONJUGATE FOR MUSCULAR DYSTROPHY
MX2019006989A (en) * 2016-12-19 2019-08-16 Sarepta Therapeutics Inc Exon skipping oligomer conjugates for muscular dystrophy.
TW201919682A (en) 2017-08-08 2019-06-01 西班牙商阿爾米雷爾有限公司 Novel compounds activating the Nrf2 pathway
EA201991450A1 (en) * 2017-09-22 2019-12-30 Сарепта Терапьютикс, Инк. OLIGOMER CONJUGATES FOR EXONISM SKIP IN MUSCULAR DYSTROPHY
WO2019060522A2 (en) * 2017-09-22 2019-03-28 The Regents Of The University Of Colorado, A Body Corporate Thiomorpholino oligonucleotides for the treatment of muscular dystrophy
WO2019067979A1 (en) 2017-09-28 2019-04-04 Sarepta Therapeutics, Inc. Combination therapies for treating muscular dystrophy
JP2020536060A (en) 2017-09-28 2020-12-10 サレプタ セラピューティクス， インコーポレイテッド Combination therapy to treat muscular dystrophy
JP2020536058A (en) 2017-09-28 2020-12-10 サレプタ セラピューティクス， インコーポレイテッド Combination therapy to treat muscular dystrophy
US20200316210A1 (en) * 2017-10-17 2020-10-08 Sarepta Therapeutics, Inc. Cell-Penetrating Peptides For Antisense Delivery
JP7394753B2 (en) 2017-10-18 2023-12-08 サレプタ セラピューティクス， インコーポレイテッド antisense oligomer compounds
JP2021521794A (en) * 2018-04-26 2021-08-30 サレプタ セラピューティクス， インコーポレイテッド Exon skipping oligomers and oligomeric conjugates for muscular dystrophy
US20220251551A1 (en) * 2018-06-13 2022-08-11 Sarepta Therapeutics, Inc. Exon skipping oligomers for muscular dystrophy
EP3806868A4 (en) 2018-06-13 2022-06-22 Sarepta Therapeutics, Inc. Exon skipping oligomers for muscular dystrophy
TW202020153A (en) 2018-07-27 2020-06-01 美商薩羅塔治療公司 Exon skipping oligomers for muscular dystrophy
TW202019442A (en) * 2018-07-30 2020-06-01 美商薩羅塔治療公司 Trimeric peptides for antisense delivery
GB201812980D0 (en) * 2018-08-09 2018-09-26 Univ Oxford Innovation Ltd Cell-penetrating peptides
US20220125934A1 (en) * 2018-12-07 2022-04-28 Oxford University Innovation Limited Linkers
JP2022511055A (en) 2018-12-13 2022-01-28 サレプタ セラピューティクス， インコーポレイテッド Exon skipping oligomer conjugate for muscular dystrophy
GB201821269D0 (en) 2018-12-28 2019-02-13 Nippon Shinyaku Co Ltd Myostatin signal inhibitor
US20220193246A1 (en) 2019-04-18 2022-06-23 Sarepta Therapeutics, Inc. Compositions for treating muscular dystrophy
CN110724180B (en) * 2019-10-17 2021-08-20 山东大学 Polypeptide for inhibiting angiogenesis and application thereof
CA3165961A1 (en) 2019-12-26 2021-07-01 Nippon Shinyaku Co., Ltd. Antisense nucleic acid that induces skipping of exon 50
IL295797A (en) 2020-02-22 2022-10-01 Japan Chem Res Human transferrin receptor binding peptide
US20230140736A1 (en) 2020-02-28 2023-05-04 Nippon Shinyaku Co., Ltd. Antisense nucleic acid inducing skipping of exon 51
MX2022010602A (en) 2020-02-28 2022-09-09 Ionis Pharmaceuticals Inc Compounds and methods for modulating smn2.
US20240024414A1 (en) * 2020-09-21 2024-01-25 Icahn School Of Medicine At Mount Sinai Archaea l30 proteins as universal influenza virus therapeutics
US20240327831A1 (en) 2020-12-23 2024-10-03 Sarepta Therapeutics, Inc. Compositions comprising exon skipping oligonucleotide conjugates for treating muscular dystrophy
CA3211038A1 (en) * 2021-02-12 2022-08-18 Oxford University Innovation Limited Cell-penetrating peptide conjugates and methods of their use
WO2022232478A1 (en) 2021-04-30 2022-11-03 Sarepta Therapeutics, Inc. Treatment methods for muscular dystrophy
TW202307208A (en) 2021-06-23 2023-02-16 日商日本新藥股份有限公司 Combination of antisense oligomers
CA3225454A1 (en) 2021-07-08 2023-01-12 Nippon Shinyaku Co., Ltd. Nephrotoxicity reducing agent
EP4368187A1 (en) 2021-07-08 2024-05-15 Nippon Shinyaku Co., Ltd. Precipitation suppressing agent
WO2023282344A1 (en) 2021-07-08 2023-01-12 日本新薬株式会社 Nephrotoxicity reducing agent
WO2023026994A1 (en) 2021-08-21 2023-03-02 武田薬品工業株式会社 Human transferrin receptor binding peptide-drug conjugate
CA3229962A1 (en) 2021-08-24 2023-03-02 Peptidream Inc. Human transferrin receptor-binding antibody-peptide conjugate
CA3233242A1 (en) 2021-09-30 2023-04-06 Sarepta Therapeutics, Inc. Antisense oligonucleotides having one or more abasic units
WO2023070086A1 (en) 2021-10-22 2023-04-27 Sarepta Therapeutics, Inc. Morpholino oligomers for treatment of peripheral myelin protein 22 related diseases
IL315280A (en) 2022-03-17 2024-10-01 Sarepta Therapeutics Inc Phosphorodiamidate morpholino oligomer conjugates
WO2024064237A2 (en) 2022-09-21 2024-03-28 Sarepta Therapeutics, Inc. Dmd antisense oligonucleotide-mediated exon skipping efficiency
US20240218365A1 (en) 2022-11-02 2024-07-04 Sarepta Therapeutics, Inc. Formulation of an antisense oligomer conjugate

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5217866A (en) 1985-03-15 1993-06-08 Anti-Gene Development Group Polynucleotide assay reagent and method
ATE171185T1 (en) 1985-03-15 1998-10-15 Antivirals Inc POLYNUCLEOTIDE IMMUNOTESTING AGENTS AND METHODS
US5166315A (en) 1989-12-20 1992-11-24 Anti-Gene Development Group Sequence-specific binding polymers for duplex nucleic acids
US5185444A (en) 1985-03-15 1993-02-09 Anti-Gene Deveopment Group Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages
US5521063A (en) 1985-03-15 1996-05-28 Antivirals Inc. Polynucleotide reagent containing chiral subunits and methods of use
US5506337A (en) 1985-03-15 1996-04-09 Antivirals Inc. Morpholino-subunit combinatorial library and method
US5034506A (en) 1985-03-15 1991-07-23 Anti-Gene Development Group Uncharged morpholino-based polymers having achiral intersubunit linkages
JPH07501204A (en) 1991-06-28 1995-02-09 マサチューセッツ インスティテュート オブ テクノロジー Topical oligonucleotide therapy
CA2135642C (en) 1992-08-21 1999-12-14 James G. Barsoum Tat-derived transport polypeptides
JPH0915828A (en) 1995-07-03 1997-01-17 Fuji Photo Film Co Ltd Paper cutter for photographic processing system
US6245747B1 (en) 1996-03-12 2001-06-12 The Board Of Regents Of The University Of Nebraska Targeted site specific antisense oligodeoxynucleotide delivery method
AU734827B2 (en) 1997-05-21 2001-06-21 Board Of Trustees Of The Leland Stanford Junior University Composition and method for enhancing transport across biological membranes
EP0998577B1 (en) * 1997-07-24 2004-10-27 Perseptive Biosystems, Inc. Conjugates of transporter peptides and nucleic acid analogs, and their use
DE19933492B4 (en) * 1999-07-16 2008-01-10 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Conjugate for the mediation of a cell-, compartment- or membrane-specific transport of active substances, process for its preparation and its use
US20020009491A1 (en) 2000-02-14 2002-01-24 Rothbard Jonathan B. Compositions and methods for enhancing drug delivery across biological membranes and tissues
JP2005508832A (en) 2001-02-16 2005-04-07 セルゲイト， インコーポレイテッド Transporter with arginine part at intervals
US20030224353A1 (en) 2001-10-16 2003-12-04 Stein David A. Antisense antiviral agent and method for treating ssRNA viral infection
WO2004097017A2 (en) 2003-04-29 2004-11-11 Avi Biopharma, Inc. Compositions for enhancing transport and antisense efficacy of nucleic acid analog into cells
AU2004276226B2 (en) 2003-08-05 2009-07-30 Avi Biopharma, Inc. Oligonucleotide analog and method for treating flavivirus infections
US20050171044A1 (en) 2003-12-24 2005-08-04 Stein David A. Oligonucleotide compound and method for treating nidovirus infections
MXPA06012605A (en) * 2004-05-04 2006-12-15 Nastech Pharm Co Compositions and methods for enhancing delivery of nucleic acids into cells and for modifying expression of target genes in cells.
US20050288246A1 (en) * 2004-05-24 2005-12-29 Iversen Patrick L Peptide conjugated, inosine-substituted antisense oligomer compound and method
EP2206781B1 (en) 2004-06-28 2015-12-02 The University Of Western Australia Antisense oligonucleotides for inducing exon skipping and methods of use thereof
US8129352B2 (en) 2004-09-16 2012-03-06 Avi Biopharma, Inc. Antisense antiviral compound and method for treating ssRNA viral infection
US8357664B2 (en) 2004-10-26 2013-01-22 Avi Biopharma, Inc. Antisense antiviral compound and method for treating influenza viral infection
US7524829B2 (en) 2004-11-01 2009-04-28 Avi Biopharma, Inc. Antisense antiviral compounds and methods for treating a filovirus infection
US7838657B2 (en) 2004-12-03 2010-11-23 University Of Massachusetts Spinal muscular atrophy (SMA) treatment via targeting of SMN2 splice site inhibitory sequences
WO2006086667A2 (en) 2005-02-09 2006-08-17 Avi Bio Pharma, Inc. Antisense composition and method for treating muscle atrophy
HUE027486T2 (en) 2005-06-23 2016-09-28 Isis Pharmaceuticals Inc Compositions and methods for modulation of SMN2 splicing
US8524676B2 (en) 2005-09-08 2013-09-03 Sarepta Therapeutics, Inc. Method for treating enterovirus or rhinovirus infection using antisense antiviral compounds
CA2621964A1 (en) 2005-09-08 2007-03-15 Avi Biopharma, Inc. Antisense antiviral compound and method for treating picornavirus infection
WO2007103529A2 (en) 2006-03-07 2007-09-13 Avi Biopharma, Inc. Antisense antiviral compound and method for treating arenavirus infection
LT2024499T (en) 2006-05-10 2018-02-26 Sarepta Therapeutics, Inc. Oligonucleotide analogs having cationic intersubunit linkages
NZ574807A (en) 2006-08-11 2011-01-28 Prosensa Technologies Bv Methods and means for treating dna repeat instability associated genetic disorders
CA2981308C (en) 2006-09-21 2020-12-22 University Of Rochester Compositions and methods related to protein displacement therapy for myotonic dystrophy
US8119686B2 (en) 2006-11-24 2012-02-21 Hykes Laboratories Llc Spiroquinone compound and pharmaceutical composition
WO2009005783A1 (en) * 2007-06-28 2009-01-08 Blanchette Rockefeller Neurosciences Institute Peptides, compositions and methods for reducing beta-amyloid-mediated apoptosis
US20100016215A1 (en) * 2007-06-29 2010-01-21 Avi Biopharma, Inc. Compound and method for treating myotonic dystrophy
EP2170363B1 (en) * 2007-06-29 2018-08-08 Sarepta Therapeutics, Inc. Tissue specific peptide conjugates and methods
BRPI0819828A8 (en) 2007-11-15 2022-12-27 Avi Biopharma Inc MORPHOLIN OLIGOMER SYNTHESIS PROCESS
MX2010006925A (en) * 2007-12-20 2011-05-02 Angiochem Inc Polypeptide-nucleic acid conjugates and uses thereof.
WO2009144481A2 (en) * 2008-05-30 2009-12-03 Isis Innovation Limited Conjugates for delivery of biologically active compounds
SI3133160T1 (en) * 2008-10-24 2019-05-31 Sarepta Therapeutics, Inc. Exon skipping compositions for dmd
WO2010072228A1 (en) * 2008-12-22 2010-07-01 Xigen S.A. Novel transporter constructs and transporter cargo conjugate molecules
WO2010120820A1 (en) 2009-04-13 2010-10-21 Isis Pharmaceuticals, Inc. Compositions and methods for modulation of smn2 splicing
DK3449926T3 (en) 2009-06-17 2019-11-11 Biogen Ma Inc COMPOSITIONS AND PROCEDURES FOR MODULATING SMN2 SPLITING BY AN INDIVIDUAL
CA2805086C (en) * 2010-05-13 2020-10-20 Sarepta Therapeutics, Inc. Antisense modulation of interleukins 17 and 23 signaling

Also Published As

Publication number Publication date
CN103619356B (en) 2017-09-12
CA3092114A1 (en) 2012-11-08
CA2834128A1 (en) 2012-11-08
EP2704749A1 (en) 2014-03-12
JP2016185991A (en) 2016-10-27
AU2017206179A1 (en) 2017-08-03
IL229227B (en) 2020-07-30
KR20140028058A (en) 2014-03-07
JP2024032974A (en) 2024-03-12
AU2021202224A1 (en) 2021-05-06
JP2014515762A (en) 2014-07-03
AU2019204913A1 (en) 2019-07-25
AU2023203112A1 (en) 2023-06-08
JP2021113232A (en) 2021-08-05
KR20210032545A (en) 2021-03-24
CN107693797A (en) 2018-02-16
IL229227A0 (en) 2014-01-30
JP2020111607A (en) 2020-07-27
KR102229650B1 (en) 2021-03-19
KR102339196B1 (en) 2021-12-15
IL273838B (en) 2022-09-01
JP6478632B2 (en) 2019-03-06
AU2011367230B2 (en) 2017-08-10
CN103619356A (en) 2014-03-05
WO2012150960A1 (en) 2012-11-08
CN107693797B (en) 2021-05-11
KR102183273B1 (en) 2020-11-27
JP2018135396A (en) 2018-08-30
AU2011367230A1 (en) 2013-12-05
JP6884250B2 (en) 2021-06-09
KR20190084351A (en) 2019-07-16

Similar Documents

Publication Publication Date Title
IL273838A (en) Peptide oligonucleotide conjugates ,compositions comprising the same and uses thereof
IL279304A (en) Cytotoxic benzodiazepine derivatives, compositions comprising the same and uses thereof
IL256921A (en) Pyrazolopyrimidines, pharmaceutical compositions comprising thereof and uses thereof
IL233154A (en) Compounds, pharmaceutical compositions comprising the same and uses thereof
IL252154A0 (en) Anti-dr5 antibodies, compositions comprising the same and uses thereof
IL236348A0 (en) Anti-jagged antibodies, compositions comprising the same and uses thereof
IL220283A0 (en) 4-oxo-ih-quinoline-3- carboxamides, compositions comprising the same and uses thereof
IL237625A0 (en) Anti-mcam antibodies, compositions comprising same and uses thereof
IL226383A0 (en) Anti-ccl20 antibodies, compositions comprising the same and uses thereof
IL228715A0 (en) Aminopyrazine compounds ,compositions comprising the same and uses thereof
IL233934A0 (en) Cd47 antibodies, compositions comprising the same and uses thereof
IL223361A (en) Purinone derivatives, compositions comprising the same and uses thereof
EP2646539A4 (en) Durable styling compositions and the uses thereof
IL228322A0 (en) Dispiropyrrolidine derivatives compositions comprising the same and uses thereof
IL216254A (en) Compounds, pharmaceutical compositions comprising the same and uses thereof
PT2588556T (en) Composition comprising 2,3,3,3-tetrafluoropropene
IL225460A0 (en) Antibodies binding 191p4d12, compositions comprising the same and uses thereof
PL2590916T3 (en) Stable 2,3,3,3-tetrafluoropropene composition
IL235004A0 (en) Anti-fgfr2 antibodies, compositions comprising same and uses thereof
IL223405B (en) Phosphaplatins, compositions comprising the same and uses thereof
HK1182934A1 (en) Anti-fatigue composition, formulation and use thereof
IL219243A (en) 5-hydroxypyrimidine-4-carboxamide derivatives, compositions comprising the same and uses thereof
IL227705A (en) Topical antifungal agent, compositions comprising the same and uses thereof
IL232383A0 (en) Anti-kdr antibodies, compositions comprising same and uses thereof
IL225464B (en) Nd2 peptides, compositions comprising the same and uses thereof